Send Inquiry

Backed by the team of expert professionals, we are engaged in manufacturing and exporting high-quality Letrozole powder. The offered powder is used as medication for the prevention and treatment of certain types of breast cancer such as hormone-receptor-positive breast cancer in women after menopause. It is a non-steroidal aromatase inhibitor that is active orally and is administered in the form of tablets. Letrozole powder works by decreasing the amount of estrogen produced by the body that helps in slowing or reversing the growth of these breast cancers.

Key Points:

  • Used for ovarian stimulation

  • Contraindicated in pregnant and breastfeeding women

  • Not recommended for pre-menopausal women

Product Name: Letrozole

CAS: 112809-51-5

MF: C17H11N5

MW: 285.3


Product Categories: Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles;ELOXATIN;Anti-cancer&immunity

Mol File: 112809-51-5.mol

Letrozole Structure

Letrozole Chemical Properties

Melting point 181-183°C

storage temp. -20°C Freezer

CAS DataBase Reference 112809-51-5(CAS DataBase Reference)

Safety Information

Hazard Codes Xi

Risk Statements 36/37/38

Safety Statements 26-36

Hazardous Substances Data 112809-51-5(Hazardous Substances Data)

MSDS Information

Provider Language

4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile English

Letrozole Usage And Synthesis

Indications and uses Letrozole is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment. Compared to the current standard Tamoxifen treatment, Letrozole can better prevent the risk of breast cancer recurrence.

Side effects Randomized grouping studies have shown that daily oral ingestion of 2.5mg Letrozole leads to a 33% rate of drug-related negative reactions, a percentage much lower than AG groups 46%. Negative reactions to Letrozole are mostly mild or moderate, consisting mostly of nausea (2-9%), headache (0-7%), bone pain (4-10%), hot flashes (0-9%) and weight gain (2-8%). Other uncommon side effects include constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, high blood pressure, arrhythmia, thrombosis, dyspnea, vaginal bleeding, etc.

Chemical Properties white to light yellow crystal

Uses A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic